Motions to Dismiss in Hatch-Waxman and Biosimilars Litigations: Key Considerations



Date & Time

Start Date: 06/09/2021
Start Time: 11:00 am
End Time: 3:00 pm EDT


Blake Coblentz and Aaron Lukas will be presenting a webinar on recent overall trends in the filing and disposition of Motions to Dismiss under Rules 12(b)(6) and 12(c). They will discuss the pleading requirements in view of Iqbal and Twombly, and examine how courts have applied the legal standard in Hatch-Waxman and biosimilars cases. They will then focus on factors particular to litigation under the Hatch-Waxman Act and BPCIA, and discuss tactics that branded and generic companies have used to better position or defend against a motion to dismiss, and factors courts have considered in denying or granting such motions. 


Share on LinkedIn


W. Blake Coblentz

Co-Chair, Hatch-Waxman & Biologics
Vice Chair, Intellectual Property

(202) 912-4837

Aaron Lukas, Ph.D.

Co-Chair, Hatch-Waxman & Biologics

(202) 912-4823

Related Practices